TRACON Pharmaceuticals is a biopharmaceutical company. Co. has a collaboration and clinical trial agreement for the development of envafolimab, an investigational PD-L1 single-domain antibody for the treatment of sarcoma in North America. Co.'s other clinical stage oncology product candidates include YH001, which is a monospecific investigational cytotoxic T-lymphocyte-associated protein 4 antibody, TRC102, which is a small molecule that has been studied in Phase 1 and Phase 2 trials for the treatment of mesothelioma, lung cancer, glioblastoma and solid tumors, and TJ004309, which is a CD73 antibody in Phase 1 clinical development for the treatment of solid tumors. We show 37 historical shares outstanding datapoints in our coverage of TCON's shares outstanding history.
Understanding the changing numbers of TCON shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like TCON versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching TCON by allowing them to research TCON shares outstanding history
as well as any other stock in our coverage universe. |
Free TCON Email Alerts:
Video: Shares Outstanding Importance
